Immunobiologic therapies for myelodysplastic syndrome

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 4 SPEC.ISS., 2004, Pages 653-661

  Appelbaum, Frederick R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

AML; Immunoconjugates; Monoclonal antibodies; Myelodysplastic syndrome

Indexed keywords

ANTIBODY CONJUGATE; BISMUTH 213; BUSULFAN; CANCER VACCINE; CD33 ANTIGEN; CD45 ANTIGEN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; ETANERCEPT; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; INFLIXIMAB; INTERLEUKIN 11; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M 195; MONOCLONAL ANTIBODY PR1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; RHENIUM 188; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNITY; BLOOD TRANSFUSION; BONE MARROW; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CELLULAR IMMUNITY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; DRUG DISTRIBUTION; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIESIS; HUMAN; HYPERBILIRUBINEMIA; IMMUNOTHERAPY; INFECTION; LIVER VENOOCCLUSIVE DISEASE; META ANALYSIS; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 5744243331     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.08.024     Document Type: Review

References (40)

1. J.E. Parker G.J. Mufti The role of apoptosis in the pathogenesis of the myelodysplastic syndromes Int J Hematol 73 2001 416-428
2. M. Kitagawa I. Saito T. Kuwata et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes Leukemia 11 1997 2049-2054
3. G.M. Gersuk C. Beckham M.R. Loken et al. A role for tumour necrosis factor-alpha. Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome Br J Haematol 103 1998 176-188
4. V. Shetty S. Mundle S. Alvi et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes Leuk Res 20 1996 891-900
5. A. Raza H. Qawi T. Andric et al. Pentoxifylline, ciprofloxacin and dexamethasone improve the ineffective hematopoiesis in myelodysplastic syndrome patients; malignancy Hematol 5 2000 275-284
6. H.J. Deeg J. Gotlib C. Beckham et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study Leukemia 16 2002 162-164
7. C. Rosenfeld C. Bedell Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome Leuk Res 26 2002 721-724
8. R. Stasi S. Amadori Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes Br J Haematol 116 2002 334-337
9. A. Raza L.A. Lisak S. Tahir et al. Hematologic improvement in response to anti-tumor necrosis factor (TNF) therapy with remicade ® in patients with myelodysplastic syndromes (MDS) Blood 100 2002 795a. [abstr.]
10. J.J. Molldrem M. Caples D. Mavroudis et al. Antithymocyte globulin for patients with myelodysplastic syndrome Br J Haematol 99 1997 699-705
11. J.J. Molldrem Y.Z. Jiang M. Stetler-Stevenson et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles Br J Haematol 102 1998 1314-1322
12. J.J. Molldrem E. Leifer E. Bahceci et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes Ann Intern Med 137 2002 156-163
13. S.B. Killick G. Mufti J.D. Cavenagh et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with low-risk myelodysplasia Br J Haematol 120 2003 679-684
14. Y. Saunthararajah R. Nakamura R. Wesley et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome Blood 102 2003 3025-3027
15. S. Yazji F. Giles H. Kantarjian et al. Antithymocyte globulin (ATG) based therapy in patients with myelodysplastic syndrome Blood 100 2002 794a. [abstr.]
16. P. Brolinden I.M. Dahl R. Hast et al. ATG and cyclosporin A as combination therapy in myelodysplastic syndromes RA and RAEB Blood 100 2002 98a. [abstr.]
17. J.K. McGavin C.M. Spencer Gemtuzumab ozogamicin Drugs 61 2001 1317-1322
18. M. Albitar T. Manshouri Y. Shen et al. Myelodysplastic syndrome is not merely preleukemia Blood 100 2002 791-798
19. E.L. Sievers R.A. Larson E.A. Stadtmauer et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 19 2001 3244-3254
20. E.L. Sievers M. Linenberger Mylotarg: antibody-targeted chemotherapy comes of age Curr Opin Oncol 13 2001 522-527
21. A. Raza P. Fenaux H. Erba et al. Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs 2 doses of gemtuzumab ozogamicin (Mylotarg ® ) in patients with high risk myelodysplastic syndrome Blood 100 2002 795a
22. E.H. Estey P.F. Thall F.J. Giles et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside Blood 99 2002 4343-4349
23. M.L. Linenberger T. Hong D. Flowers et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin Blood 98 2001 988-994
24. A. Tsimberidou J. Cortes D. Thomas et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia Leuk Res 27 2003 893-897
25. H.J. Deeg F.R. Appelbaum Hemopoietic stem cell transplantation for myelodysplastic syndrome Curr Opin Oncol 12 2000 116-120
26. R.H. van der Jagt C.C. Badger F.R. Appelbaum et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model Cancer Res 52 1992 89-94
27. D.C. Matthews F.R. Appelbaum J.F. Eary et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation Blood 85 1995 1122-1131
28. D.C. Matthews F.R. Appelbaum J.F. Eary et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome Blood 94 1999 1237-1247
29. E. Rosario J. Rajendran K.L. Ruffner et al. Radiolabeled anti-CD45 antibody with cyclophosphasmide (CY) and total body irradiation (TBI) followed by allogeneic hemotopoietic stem cells transplantation (HSCT) for patients with advanced acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) Blood 98 2001 857a. [abstr.]
30. F.R. Appelbaum D.C. Matthews J.F. Eary et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia Transplantation 54 1992 829-833
31. J.G. Jurcic S.M. Larson G. Sgouros et al. Targeted alpha particle immunotherapy for myeloid leukemia Blood 100 2002 1233-1239
32. D. Bunjes I. Buchmann C. Duncker et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study Blood 98 2001 565-572
33. D. Bunjes 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia Leuk Lymphoma 43 2002 2125-2131
34. R. Storb C. Yu P. McSweeney Mixed chimerism after transplantation of allogeneic hematopoietic cells In Hematopoietic Cell Transplantation 2nd edn 1999 Blackwell Science Boston 287-295
35. J.E. Parker T. Shafi A. Pagliuca et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens Br J Haematol 119 2002 144-154
36. H. Sugiyama Cancer immunotherapy targeting WT1 protein Int J Hematol 76 2002 127-132
37. C. Rosenfeld M.A. Cheever A. Gaiger WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies Leukemia 17 2003 1301-1312
38. D. Cilloni E. Gottardi F. Messa et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes J Clin Oncol 21 2003 1988-1995
39. O.A. Elisseeva Y. Oka A. Tsuboi et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies Blood 99 2002 3272-3279
40. E.D. Weider S. Kant S. Lu et al. PR1 peptide vaccination of myeloid leukemia patients induces PR1-specific CTL with high CCR7 expression Blood 102 2003 611a. [abstr.]